Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • Industry Snapshot
    • MassBioHub – Conference Center
    • COVID-19 Resource Center
    • Innovation Services
    • Policy & Advocacy
    • Economic Development
    • Career Center
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Pricing
    • Virtual Member Benefits
    • Member News
    • Become a Member
    • Pay Company Dues
  • MassBio Edge
    • MassBio Edge
    • Preferred Partners
    • Employee Rewards
    • Edge Benefits
  • Initiatives
    • State of Possible 2025 Report
    • Equity, Diversity, and Inclusion
    • Open Letter 2.0 – CEO Pledge for ED&I
    • Value of Health
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • MassBioEd
    • FAQs
    • Contact Us
  • News
    • News & Thought Leadership
    • State of Possible Podcast
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Agenus

Life Sciences | Drug Development
Lexington, MA 781-674-4400 Website https://twitter.com/agenus_bio?lang=en LinkedIn Facebook

Overview

Headquartered in Greater Boston in Lexington, Massachusetts, Agenus is a biotechnology company working in immuno-oncology. Immuno-oncology is a field that harnesses the power of the immune system to control or cure cancer. Through its research centers located in Lexington, Massachusetts, Berkeley, California and Cambridge, UK, Agenus is developing a range of immunotherapies, including checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and vaccine adjuvants. CPM development is a particularly fast-moving field where early products produced unprecedented clinical benefits for patients. Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte Display® generates fully human therapeutic antibody drug candidates.

Founded in 1994, Agenus platforms are extensively partnered with GlaxoSmithKline, Janssen and Merck. Among Agenus and its partners, more than 20 programs are in clinical development.

At Agenus, we are dedicated to the development of life-changing medicines. Our employees solve complex problems through a culture of innovation, cross-functional teamwork, and commitment to our purpose. We are looking for people who are passionate about our mission and excited by the challenge of working as partners in a rapidly changing landscape.

Company News

News

Agenus Announces New Responses for AGEN1181

Feb 16, 2021

Posted by Agenus

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2021 All Rights Reserved